Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine

Biochemical Pharmacology

Volumn 52, Issue 10, 1996, Pages 1545-1552

  Riffkin, Christopher D ^a   Chung, Roland ^a   Wall, Dominic M ^c   Zalcberg, John R ^c   Cowman, Alan F ^b   Foley, Michael ^a   Tilley, Leann ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c NONE

Author keywords

mefloquine; multidrug resistance; P glycoprotein; quinoline antimalarials

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; GLYCOPROTEIN P; MEFLOQUINE; PRAZOSIN; VERAPAMIL; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; TUMOR CELL;

AFFINITY LABELS; ANTIMALARIALS; BINDING SITES; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT, ACTIVE; CHLOROQUINE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FLUORESCENT DYES; HUMANS; KINETICS; MEFLOQUINE; NEOPLASMS; P-GLYCOPROTEIN; PRAZOSIN; TUMOR CELLS, CULTURED; VERAPAMIL; VINBLASTINE;

EID: 0030598403     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00556-4     Document Type: Article

References (43)

1. 1. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
2. 2. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J and Ling V, Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817-819, 1985.
3. 3. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL and Felsted RL, Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884-7888, 1987.
4. 4. Greenberger LM, Major photoaffinity drug labelling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268: 11417-11425, 1993.
5. 5. Ford JM and Hait WN, Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
6. 6. Wigler PW and Patterson FK, Inhibition of the multidrug resistance efflux pump. Biochim Biophys Acta 1154: 173-181, 1993.
7. 7. Safa AR, Photoaffinity labelling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 85: 7187-7191, 1988.
8. 8. Boer R, Dichtl M, Borchers C, Ulrich WR, Marecek JF, Prestwich GD, Glossmann H and Striessnig J, Reversible labeling of a chemosensitizer binding domain of P-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35: 1387-1396, 1996.
9. 9. Ferry DR, Russell MA and Cullen MH, P-Glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site. Biochim Biophys Res Commun 188: 440-445, 1992.
10. 10. Sikic BI, Modulation of multidrug resistance: At the threshold. J Clin Oncol 11: 1629-1635, 1993.
11. 11. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI, Clinical trials of modulation of multidrug resistance. Cancer 72 (Suppl): 3502-3514, 1993.
12. 12. Akiyama S-I, Cornwell MM, Kuwano M, Pastan I and Gottesman MM, Most drugs that reverse multidrug resistance also inhibit photoaffinity labelling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 33: 144-147, 1988.
13. 13. Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M and Guy H, Sufficient levels of quinine in serum circumvent the multidrug resistance of the leukemic cell line K562/ADM. Cancer 68: 1714-1718, 1991.
14. 14. Beck WT, Cirtain MC, Glover CJ, Felsted RL and Safa AR, Effects of indole alkaloids on multidrug resistance and labelling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun 153: 959-966, 1988.
15. 15. Solary E, Caillot D, Chauffert B, Casasnovas R-O, Dumas M, Maynadie M and Guy H, Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10: 1730-1736, 1992.
16. 16. Genne P, Duchamp O, Solary E, Pinard D, Belon JP, Dimanche-Boitrel MT and Chauffert B, Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia 8: 160-164, 1994.
17. 17. Genne P, Duchamp O, Solary E, Magnette J, Belon JP and Chauffert B, Cinchonine per os: Efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des 10: 103-118, 1995.
18. 18. San George RC, Nagel RL and Fabry ME, On the mechanism of the red cell accumulation of mefloquine, an antimalarial drug. Biochim Biophys Acta 803: 174-181, 1984.
19. 19. Schwartz DE, Eckert G, Hartmann D, Weber B, Richard-Lenoble D, Ekue JMK and Gentilini M, Single dose kinetics of mefloquine in man. Chemotherapy 28: 70-84, 1982.
20. 20. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK and White NJ, High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 166: 1393-1400, 1992.
21. 21. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA and McCarthy RE, Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18: 522-529, 1965.
22. 22. Zalcberg JR, Hu XF, Wall DM, Mirski S, Cole S, Nadalin G, De Luise M, Parkin JD, Vrazas V, Cambell L and Kantharidis P, Cellular and karyotypic characterization of two doxorubicin-resistant cell lines isolated from the same parental human leukemic cell line. Int J Cancer 57: 522-528, 1994.
23. 23. Beck WT, Mueller TJ and Tanzer LR, Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070-2076, 1979.
24. 24. Beck WT, Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat Rep 67: 875-882, 1983.
25. 25. Zalcberg JR, Hu XF, Ching M, Wakeling A, Wall DM, Marschner IC and De Luise M, Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines. Cancer Chemother Pharmacol 33: 123-129, 1993.
26. 26. Peterson RHF, Meyers MB, Spengler BA and Biedler JL, Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster ovary cells accompanying development of resistance to daunorubicin. Cancer Res 43: 222-228, 1983.
27. 27. Wall DM, Hu XF, Zalcberg JR and Parkin JD, Rapid functional assay for multidrug resistance in human tumor cell lines using the fluorescent indicator fluo-3. J Natl Cancer Inst 3: 206-207, 1991.
28. 28. Wall DM, Sparrow R, Hu XF, Nadalin G, Zalcberg JR, Marschner IC, Van Der Weyden M and Parkin JD, Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3. Eur J Cancer 29A: 1024-1027, 1993.
29. 29. Coon JS, Wang Y and Bines SD, Multidrug resistance activity in human lymphocytes. Hum lmmunol 32: 134-140, 1991.
30. 30. Kessel D, Beck WT, Kukuruga D and Schulz V, Characterization of multidrug resistance by fluorescent dyes. Cancer Res 51: 4665-4670, 1991.
31. 31. Hu XF, Martin TJ, Bell DR, De Luise M and Zalcberg JR, Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957, 1990.
32. 32. Hu XF, De Luise M, Martin TJ and Zalcberg JR, Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin. Eur J Cancer 26: 814-817, 1990.
33. 33. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698, 1989.
34. 34. Holash JA, Harik SI, Perry G and Stewart PA, Barrier properties of testis microvessels. Proc Natl Acad Sci USA 90: 11069-11073, 1993.
35. 35. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P, Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
36. 36. Wang Q, Yang H, Miller DW, and Elmquist WF, Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 211: 719-726, 1995.
37. 37. Luxemburger C, Nosten F, ter Kuile F, Frejacques L, Chongsuphajaisiddhi T and White NJ, Mefloquine for multidrug-resistant malaria. Lancet 338: 1268, 1991.
38. 38. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W and Phole HD, Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45: 86-91, 1991.
39. 39. Bem JL, Kerr L and Stuerchler D, Mefloquine prophylaxis: An overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 95: 167-179, 1992.
40. 40. Hennequin C, Bourée P, Bazin N, Bisaro F and Feline A, Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med 154: 2360-2362, 1994.
41. 41. Wittes RC and Saginur R, Adverse reaction to mefloquine associated with ethanol ingestion. Can Med Assoc J 152: 515-517, 1995.
42. 42. White NJ, Mefloquine. In the prophylaxis and treatment of falciparum malaria. Br Med J 308: 286-287, 1994.
43. 43. Osimitz TG and Grothaus RH, The present safety assessment of DEET. J Am Mosq Control Assoc 11: 274-278, 1995.